Consumer News Eli Lilly Says Its New Diabetes Drug Was 94 Effective In Clinical Trials

Eli Lilly: High Growth Driven by GLP-1 Drugs and Potential Challenges

Investing in pharmaceutical companies with robust product pipelines and diversified revenue streams is often considered a strategy with potential. Eli Lilly (LLY) recently reported outstanding ... Read More

Eli Lilly says weight-loss pill a candidate for speedy approval under new US program

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate for a ... Read More

Eli Lilly's Weight-Loss Drug Meets Primary Endpoint in Diabetes Trials

Eli Lilly said its investigational oral GLP-1 weight-loss drug, orforglipron, met its primary endpoints in two recent phase 3 trials. The medicine company said Wednesday the drug met the primary and ... Read More

Lilly's weight-loss pill shows better blood sugar control in late-stage trials

FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo (Reuters) -Eli Lilly's experimental ... Read More

Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially been surpassed by Eli Lilly. Read More

Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials

Eli Lilly and Company (LLY) on Wednesday said that its oral GLP-1 drug Orforglipron lowered blood glucose levels in two late-stage trials, confirming its potential in treating type-2 diabetes. While ... Read More

Eli Lilly oral weight loss drug succeeds in late-stage trials for diabetes

Eli Lilly (NYSE:LLY) announced on Wednesday that its oral weight loss candidate, orforglipron, reached the main goals in two Phase 3 trials for patients with type 2 diabetes, indicating its potential ... Read More

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House

Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports indicating the company is close to finalizing a White House agreement to ... Read More

Eli Lilly’s New Study: Potential Breakthrough in Type 1 Diabetes Prevention

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is conducting a Phase 3 ... Read More